SCHEMBL22479906

SCHEMBL22479906

O=C(OCc1ccccc1)O[C@@H]1OC(CO[C@@H]2OC(CO[C@@H]3OC(CO)[C@H](O)C(O)C3O)[C@H](O)C(O[C@H]3O[C@@H](CO[C@@H]4O[C@@H](CO)C(O)C4O)C(O)C3O)C2O)[C@H](O)C(O)C1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 1/20 0.52
SLC6A2 P23975 2/20 0.50
FGF1 P05230 1/20 0.48
FGF2 P09038 1/20 0.48
VEGFA P15692 1/20 0.48
HPSE Q9Y251 1/20 0.48
CD209 Q9NNX6 2/20 0.47
PRKCA P17252 1/20 0.46
ENGASE Q8NFI3 1/20 0.44
LGALS9 O00182 1/20 0.43
LGALS1 P09382 1/20 0.43
LGALS3 P17931 1/20 0.43
LGALS7; LGALS7B P47929 1/20 0.43
HRAS P01112 1/20 0.43
MAOB P27338 1/20 0.43
SYNJ2 O15056 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ABL1 P00519 1/20 0.42
ALPL P05186 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14974646 0.88 SLC6A2 (0.60) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL14975583 0.88 SLC6A2 (0.60) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL14974644 0.88 SLC6A2 (0.60) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL20169021 0.86 LGALS8 (0.56) LGALS8SLC6A2MAOBSYNJ2KDM4E
SCHEMBL24807539 0.83 LGALS8 (0.60) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL14975585 0.81 SLC6A2 (0.57) SLC6A2FGF1FGF2VEGFAHPSE
SCHEMBL14974641 0.81 SLC6A2 (0.57) SLC6A2FGF1FGF2VEGFAHPSE
SCHEMBL29894477 0.79 LGALS8 (0.47) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL16620344 0.79 LGALS8 (0.47) LGALS8SLC6A2FGF1FGF2VEGFA
SCHEMBL30891482 0.79 LGALS8 (0.47) LGALS8SLC6A2FGF1FGF2VEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11179407-B2 Method for synthetically producing arabinogalactan compounds derived from plants and uses of said compounds for the prophylaxis of allergic reactions FORSCHUNGSZENTRUM BORSTEL LEIBNIZ-ZENTRUM FÜR MEDIZIN UND BIOWISSENSHAFTEN (DE) 2021-11-23 US disclosed
US-20200306279-A1 METHOD FOR SYNTHETICALLY PRODUCING ARABINOGALACTAN COMPOUNDS DERIVED FROM PLANTS AND USES OF SAID COMPOUNDS FOR THE PROPHYLAXIS OF ALLERGIC REACTIONS RUHR-UNIVERSITäT BOCHUM (DE) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306279-A1 METHOD FOR SYNTHETICALLY PRODUCING ARABINOGALACTAN COMPOUNDS DERIVED FROM PLANTS AND USES OF SAID COMPOUNDS FOR THE PROPHYLAXIS OF ALLERGIC REACTIONS FUT5, FUT6, ALG1 LGALS8 83/4885SLC6A2 4098/4885FGF1 3602/4885
US-11179407-B2 Method for synthetically producing arabinogalactan compounds derived from plants and uses of said compounds for the prophylaxis of allergic reactions FUT5, FUT6, ALG1 LGALS8 83/4885SLC6A2 4098/4885FGF1 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.